Buck, Stefan A. J. http://orcid.org/0000-0003-1367-8403
Guchelaar, Niels A. D.
de Bruijn, Peter
Ghobadi Moghaddam-Helmantel, Inge M.
Oomen-de Hoop, Esther
Westgeest, Hans M.
Hamberg, Paul
Mathijssen-van Stein, Danielle
Lolkema, Martijn P.
Koolen, Stijn L. W.
de Wit, Ronald
Mathijssen, Ron H. J.
Funding for this research was provided by:
Bayer
Article History
Accepted: 10 July 2022
First Online: 27 July 2022
Declarations
:
: Bayer provided funding for the preparation of this article.
: HW: honoraria; Astellas and Roche and travel expenses; Astellas and Ipsen. PH: consulting fees; Astellas, MSD, Pfizer, AstraZeneca, BMS and Ipsen. MPL: advisory role/speaker fees; Incyte, Amgen, Janssen Cilag B.V., Bayer, Servier, Roche, Pfizer Sanofi Aventis Netherlands BV and Astellas and has received research funding (institutional) from Sanofi, JnJ, Merck and Astellas. RDW: advisory role/speaker fees; Sanofi, Merck, Lilly, Roche, Bayer, Janssen Cilag B.V. and Clovis and research funding (institutional); Sanofi and Bayer. RHJM: has received research funding (institutional) from Bayer, Sanofi and Astellas.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: Conceptualisation: SB, RdW, RM; methodology: SB, RM, SK, PdB; formal analysis: SB, EOdH; investigation: SB, NG; resources: PdB, SB; data curation: SB, NG, writing, original draft: SB; writing, review and editing: all authors.